SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024)
MWN-AI** Summary
SANUWAVE Health, Inc. (OTCQB: SNWV), a prominent provider of advanced FDA-approved wound care products, has announced preliminary revenue results for the fourth quarter of 2024, reporting revenues between $10.1 million to $10.3 million. This achievement marks the highest quarterly revenue in the company’s history and signifies an impressive increase of 44% to 47% compared to Q4 2023. A notable contributor to this surge is the company's UltraMist technology, which saw revenue growth of over 54% year-on-year, constituting approximately 98% of total revenues for the quarter. With UltraMist applicator sales at an all-time quarterly high, they represented 58% of overall revenues.
For the full year 2024, SANUWAVE expects annual revenues in the range of $32.4 million to $32.6 million, reflecting a substantial growth of 59% to 60% from 2023. CEO Morgan Frank expressed enthusiasm for the company's performance, stating that the fourth quarter marked their third consecutive record revenue quarter and reflected a successful phase of rapid, profitable growth.
The complete fourth-quarter and annual financial results are anticipated in March 2025. SANUWAVE focuses on developing and commercializing innovative medical systems aimed at improving wound healing and tissue regeneration. They utilize patented energy transfer technologies across various medical fields, including orthopedic, cosmetic, and cardiac applications.
While the preliminary results are optimistic, SANUWAVE cautioned investors regarding forward-looking statements, emphasizing the inherent risks and uncertainties that could impact future performance. The company advises stakeholders to consider potential challenges related to supply chain dynamics, regulatory compliance, and competitive pressures as it moves forward.
MWN-AI** Analysis
SANUWAVE Health’s recent announcement of preliminary revenue results for Q4 2024 indicates significant growth, with revenues expected to reach between $10.1 million and $10.3 million, a notable increase of 44% to 47% compared to Q4 2023. This upward trajectory underscores SANUWAVE’s strengthening position in the wound care market, driven primarily by a remarkable 54% increase in UltraMist revenues, which accounted for approximately 98% of total revenue.
Given that SANUWAVE has now marked its third consecutive quarter of record revenues, with preliminary annual results showcasing a 59-60% growth from the previous year, there are several implications for potential investors. Firstly, this momentum suggests that SANUWAVE is not only capitalizing on its current product lines but is also laying a solid foundation for continued expansion and scalability. Moreover, the anticipated release of full Q4 and annual results later this March could provide additional insights into the company’s operational efficiencies and growth strategies.
Investors should also consider the competitive landscape and the challenges posed by potential supply chain issues and regulatory scrutiny, which SANUWAVE has acknowledged. As the company navigates these uncertainties, maintaining a watchful eye on its operational capabilities and management strategies will be vital.
In summary, SANUWAVE Health appears to be on a positive growth trajectory, bolstered by impressive sales performance in 2024. For investors, the company represents a potential growth opportunity in a niche medical technology sector. However, due diligence and attention to forthcoming financial disclosures will be crucial to fully understand the sustainability of this growth. Considering these factors, potential investors may find it beneficial to closely monitor SANUWAVE as it moves through what is projected to be an exciting phase for the company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SANUWAVE is pleased to announce preliminary revenues of $10.1 million to $10.3 million for the fourth quarter ended December 31, 2024. This represents the highest quarterly revenues in company history.
Q4 2024 revenue increased between 44% and 47% compared to Q4 2023.
UltraMist revenues for Q4 2024 increased by more than 54% versus Q4 2023 and accounted for approximately 98% of the Company’s total revenues.
UltraMist applicator sales were an all-time quarterly record and were approximately 58% of total revenues.
Preliminary annual revenue for full year 2024 is $32.4-$32.6 million, up 59-60% vs full year 2023.
EDEN PRAIRIE, MN - January 13, 2025 (NEWMEDIAWIRE) - SANUWAVE Health, Inc. (the "Company" or " SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the fourth quarter of 2024 are expected to be in the range of $10.1 to $10.3 million, an increase of 44% to 47% over Q4 2023 and consistent with the upper end of the range of guidance given in the Company’s Q3 2024 earnings release from November 8, 2024.
“Q4 was our third consecutive all-time record revenue quarter and brings us to annual revenue growth in the neighborhood of 60%,” said CEO Morgan Frank. “Obviously, this is a neighborhood we’re pleased to be in. 2024 has been a breakout year for SANUWAVE and a strong first step in the pursuit of our plan of rapid, profitable growth. We have never been more excited about where we are or for the prospects of what’s to come. The Company plans to release its full Q4 and annual results in or around the 3rd week of March and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2024, and may be subject to adjustments based on the Company’s completion of its quarter-end and annual financial close process.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
View the original release on www.newmediawire.com
FAQ**
Given the preliminary revenues for Q4 2024, what specific strategies contributed to the significant growth of UltraMist revenues, which represented 98% of total revenues for SANUWAVE Health Inc SNWV?
How does SANUWAVE Health Inc SNWV intend to sustain its momentum after achieving record quarterly revenues, especially in light of potential risks mentioned in the forward-looking statements?
Can SANUWAVE Health Inc SNWV provide insights into the competitive landscape and how it plans to differentiate its wound care solutions moving forward, considering the impressive annual revenue growth reported?
What are the key factors that SANUWAVE Health Inc SNWV believes will drive continued revenue growth in 2025, especially following this breakout year in 2024?
**MWN-AI FAQ is based on asking OpenAI questions about SANUWAVE Health Inc. (NASDAQ: SNWV).
NASDAQ: SNWV
SNWV Trading
-11.01% G/L:
$17.21 Last:
64,631 Volume:
$18.94 Open:
